A 24-week, randomised, open-label, parallel-group, multi-centre study which compares the efficacy and safety of rosuvastatin 10, 20 and 40 mg with atorvastatin 10, 20 40 and 80 mg when force titrated in the treatment of patients with primary hypercholesterolemia and either a history of coronary heart disease (CHD) or clinical evidence of atherosclerosis or a CHD risk equivalent (10 year risk score >20%).

Study identifier:4522IL/0101

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 24-week, randomised, open-label, parallel-group, multi-centre study which compares the efficacy and safety of rosuvastatin 10, 20 and 40 mg with atorvastatin 10, 20 40 and 80 mg when force titrated in the treatment of patients with primary hypercholesterolemia and either a history of coronary heart disease (CHD) or clinical evidence of atherosclerosis or a CHD risk equivalent (10 year risk score >20%).

Medical condition

hypercholesterolaemia

Phase

Phase 1

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Jan 1971

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here